Data from Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors

Autor: Mrinal M. Gounder, Khashayarsha Khazaie, Mary Varterasian, Brent Kreider, David Tung, Alexey A. Leontovich, Saurabh Saha, Linping Zhang, Ronald L. Korn, Jennifer L. Salstrom, Maria Miller, Amanda Collins, Gary DeCrescenzo, Ernest Trevino, Alice Weissfeld, Stephen B. Solomon, Jean Torrisi, Anjali Raina, Divya Sakamuri, Steven Y. Huang, Mark Klang, Daniel D. Karp, Sarina A. Piha-Paul, David S. Hong, Tyler Masters, Thorunn Helgason, Dale R. Shepard, Andrea Wang-Gillam, Ravi Murthy, Sanjay Goel, Abdulmohammad Pezeshki, Halle Huihong Zhang, Filip Janku

Purpose:Intratumorally injected Clostridium novyi-NT (nontoxic; lacking the alpha toxin), an attenuated strain of C. novyi, replicates within hypoxic tumor regions resulting in tumor-confined cell lysis and inflammatory response in animals, which war

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ee8c35e7baa12ec727650c1b68bd0ce
https://doi.org/10.1158/1078-0432.c.6529983.v1

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

Autor: Ahmed Omar Kaseb, Elshad Hasanov, Hop Sanderson Tran Cao, Lianchun Xiao, Jean-Nicolas Vauthey, Sunyoung S Lee, Betul Gok Yavuz, Yehia I Mohamed, Aliya Qayyum, Sonali Jindal, Fei Duan, Sreyashi Basu, Shalini S Yadav, Courtney Nicholas, Jing Jing Sun, Kanwal Pratap Singh Raghav, Asif Rashid, Kristen Carter, Yun Shin Chun, Ching-Wei David Tzeng, Divya Sakamuri, Li Xu, Ryan Sun, Vittorio Cristini, Laura Beretta, James C Yao, Robert A Wolff, James Patrick Allison, Padmanee Sharma

Publikováno v: Lancet Gastroenterol Hepatol
Kaseb, A O, Hasanov, E, Cao, H S T, Xiao, L, Vauthey, J N, Lee, S S, Yavuz, B G, Mohamed, Y I, Qayyum, A, Jindal, S, Duan, F, Basu, S, Yadav, S S, Nicholas, C, Sun, J J, Singh Raghav, K P, Rashid, A, Carter, K, Chun, Y S, Tzeng, C W D, Sakamuri, D, Xu, L, Sun, R, Cristini, V, Beretta, L, Yao, J C, Wolff, R A, Allison, J P & Sharma, P 2022, ' Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma : a randomised, open-label, phase 2 trial ', The Lancet Gastroenterology and Hepatology, vol. 7, no. 3, pp. 208-218 . https://doi.org/10.1016/S2468-1253(21)00427-1

Background: Hepatocellular carcinoma has high recurrence rates after surgery; however, there are no approved standard-of-care neoadjuvant or adjuvant therapies. Immunotherapy has been shown to improve survival in advanced hepatocellular carcinoma; we

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38276e79aeed564d05882604eb17143a
https://doi.org/10.1016/s2468-1253(21)00427-1

Intratumoral Injection of

Autor: Filip, Janku, Halle Huihong, Zhang, Abdulmohammad, Pezeshki, Sanjay, Goel, Ravi, Murthy, Andrea, Wang-Gillam, Dale R, Shepard, Thorunn, Helgason, Tyler, Masters, David S, Hong, Sarina A, Piha-Paul, Daniel D, Karp, Mark, Klang, Steven Y, Huang, Divya, Sakamuri, Anjali, Raina, Jean, Torrisi, Stephen B, Solomon, Alice, Weissfeld, Ernest, Trevino, Gary, DeCrescenzo, Amanda, Collins, Maria, Miller, Jennifer L, Salstrom, Ronald L, Korn, Linping, Zhang, Saurabh, Saha, Alexey A, Leontovich, David, Tung, Brent, Kreider, Mary, Varterasian, Khashayarsha, Khazaie, Mrinal M, Gounder

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 27(1)

Intratumorally injectedThis first-in-human study (NCT01924689) enrolled patients with injectable, treatment-refractory solid tumors to receive a single intratumoral injection ofAmong 24 patients, a single intratumoral injection ofSingle intratumoral

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0c30bd94fe50e24e6dc03247153acc93
https://pubmed.ncbi.nlm.nih.gov/33046513

Phase I Dose-Escalation Study of Anti–CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers

Autor: Jennifer J. Wheler, Michelle A. Fanale, Apostolia Maria Tsimberidou, Isabella C. Glitza, Filip Janku, Sonia L. Betancourt Cuellar, Maria E. Cabanillas, Vivek Subbiah, David S. Hong, Gerald S. Falchook, Siqing Fu, Aung Naing, Divya Sakamuri

Publikováno v: Molecular Cancer Therapeutics. 17:671-676

Preclinical data suggest that combining a checkpoint inhibition with immunomodulatory derivative can increase anticancer response. We designed a dose-escalation study using a 3 + 3 design to determine the safety, maximum tolerated dose (MTD) or recom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c0121a98c40d126233bf8d6c63b75316
https://doi.org/10.1158/1535-7163.mct-17-0673

Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC

Autor: Ahmed Omar Kaseb, Roberto Carmagnani Pestana, Luis M. Vence, Jorge M. Blando, Shalini Singh, Naruhiko Ikoma, Kanwal Pratap Singh Raghav, Divya Sakamuri, Lauren Girard, Dongfeng Tan, Jean-Nicolas Vauthey, Ching-Wei David Tzeng, Thomas A. Aloia, Yun Shin Chun, James C. Yao, Robert A. Wolff, James Patrick Allison, Padmanee Sharma

Publikováno v: Journal of Clinical Oncology. 37:4098-4098

4098 Background: In HCC, surgical resection is associated with high recurrence rate, and no effective neoadjuvant or adjuvant therapies currently exist. On the basis of of previous reports on the efficacy and safety of anti–PD-1 (nivolumab) and ant

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2ca3217e504885367d0640272f61a9a7
https://doi.org/10.1200/jco.2019.37.15_suppl.4098